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ABSTRACT 
 
 The Rift Valley Fever virus (RVFV) presents an epidemic and epizootic threat in 
sub-Saharan Africa, Egypt, and the Arabian Peninsula, and has recently gained attention 
as a potential weapon of bioterrorism due to its ability to infect both livestock and 
humans. Inbred rat strains show similar characteristic responses to the disease as humans 
and livestock, making them a suitable model species. Previous studies had shown 
differences among various inbred rat strains in susceptibility to RVFV hepatic disease, 
including a higher susceptibility of Wistar-Furth (WF) rats compared to a more resistant 
Lewis (LEW) strain. Further study revealed that this resistance trait follows the pattern 
of a dominant gene inherited in Mendelian fashion. A congenic WF.LEW strain resistant 
to infection with RVFV was derived from the susceptible WF and resistant LEW strains, 
and a subsequent genome scan revealed two prospective regions for the location of the 
gene, one on chromosome 3 and the other on chromosome 9. Subsequently, this study 
employed the methods of backcrossing, genotyping, viral challenges, gene expression 
studies, and sequencing to define a practicable region of interest and to further identify a 
viable candidate gene and prospective mechanism by which resistance is conferred. 
 A program of backcrossing WF.LEW rats to WF rats, genotyping offspring using 
SNPs and microsatellites, and subsequently challenging N1 litters with RVFV was used 
to determine that the ~2Mb region on the distal end of chromosome 3 contains the gene 
conferring resistance. The use of genetic markers to detect recombination in further 
backcross generations resulted in the identification of two recombinants in this newly 
 iii 
 
established region of interest. Through RVFV challenges, the recombinants narrowed 
the prospective region of chromosome 3 to ~500Kb containing 20 genes. Comparative 
qPCR analysis of all 20 genes combined with comparative sequencing studies of the 
entire region between susceptible WF/NHsd rats and resistant WF.LEW rats facilitated 
the identification of candidate gene Rtel1 and a proposed mechanism by which 
resistance is conferred, which will potentially become the basis for developing new 
preventive measures against the virus. 
 
 iv 
 
ACKNOWLEDGEMENTS 
 
The author would like to thank her committee chair, Dr. James Womack, and her 
committee members, Dr. Duane Kraemer, Dr. Loren Skow, and Dr. Jane Welsh, for their 
guidance and support throughout the course of this research. 
Thanks also go to Dr. Erin Gillenwaters Flores, Dr. Brittany Jones, Junfeng 
Chen, Jan Elliott, Elaine Owens, Christie Fickey, Dr. John Morrill, Dr. C.J. Peters, Dr. 
Ralph Callicott, Dr. Christopher Seabury, Dr. Sarah Black, and Dr. Jessica Nerren for 
their invaluable assistance, advice, training, and reflection during the course of this 
study. 
Finally, thanks to the author’s family and friends for their patience, love, 
encouragement, and prayers throughout this process. 
 v 
 
NOMENCLATURE 
 
CNV Copy-number variation 
DIP Deletion / insertion polymorphism 
IFN Interferon 
LEW Lewis 
N1 First backcross generation 
NSs Non-structural protein of the S segment 
qPCR Quantitative polymerase chain reaction 
Q.S. Quantity sufficient 
R1 First recombinant generation 
ROI Region of interest 
RNO3 Rat chromosome 3 
RNO9 Rat chromosome 9 
RVFV Rift Valley Fever virus 
SNP Single nucleotide polymorphism 
SSLP Simple sequence length polymorphism 
UTR Untranslated region 
VHF Viral hemorrhagic fever 
WF Wistar Furth 
WF.LEW Wistar Furth / Lewis congenic strain 
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CHAPTER I 
 INTRODUCTION: RIFT VALLEY FEVER VIRUS AND INBRED RAT 
STRAINS  
 
Introduction to Rift Valley Fever Virus 
 Rift Valley Fever (RVF) virus is an arthropod-borne phlebovirus of the family 
Bunyaviridae that can cause severe epizootic disease in both human and animal hosts, 
mainly infecting domesticated livestock such as sheep, cattle, and goats, but also 
infecting camels, buffalo, monkeys, and gray squirrels as well as other rodents [1-3]. It 
was first identified in a 1930 outbreak in sheep in the greater Rift Valley of Kenya [4,5], 
and while originally endemic to sub-Saharan Africa, the disease has demonstrated 
ecologic flexibility by spreading across the continent from Egypt in the north [6,7] to 
South Africa in the south [8,9], from Kenya in the east [4,10] to Senegal and Mauritania 
in the west [11-15], and even extending its reach outside of the African continent to the 
island of Madagascar [16] and into Saudi Arabia and Yemen in the Arabian Peninsula 
[17-19]. The disease has not only displayed the ability to emerge in new regions but also 
to re-emerge after long periods of silence in endemic regions, as seen in Somalia, Kenya, 
and Tanzania in 2006 [20,21] and in South Africa in 2010 [22]. This viral competency 
combined with the presence of potential vectors in currently RVF-free regions such as 
Europe [23] and the USA [24,25], an increase in international trade in live animals, and 
the uncertain effects of climate change, have all led to concerns about the introduction of 
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RVF into RVF-free countries, prompting preparations, preventive measures, and 
warnings from numerous national and international agencies [20,26-34]. 
 
Viral Structure 
The Rift Valley Fever virus (RVFV) is an enveloped RNA virus with a negative-
sense, single-stranded, tripartite RNA genome. This genome’s three segments are 
identified as L (large), M (medium), and S (small), and they encode a total of seven 
proteins with various functions [35]. These are the L protein (viral RNA-dependent RNA 
polymerase) coded for by the L segment, the glycoproteins G1 (Gc) and G2 (Gn) along 
with the two non-structural proteins NSm1 (78 kDa) and NSm2 (14 kDa), all encoded by 
the M segment, and the nucleoprotein N and non-structural protein NSs encoded by the 
S segment [20,36-40]. The viral envelope glycoproteins are essential for penetration into 
host cells; these are also recognized by the host’s immune system and induce the 
production of neutralizing antibodies [20]. NSm2 has anti-apoptotic function and 
contributes to pathogenesis [41]. NSs, meanwhile, has been identified as a major factor 
of virulence (primarily as an interferon antagonist), being largely responsible for the 
ability of the virus to evade the host antiviral response and playing an important role in 
viral replication and pathogenesis [20,42-45]. NSs is a multifunctional protein, 
responsible for inhibiting general cellular transcription in addition to suppressing two 
separate aspects of the interferon response [44,45]. Within the first 3-4 hours of RVFV 
infection, NSs works to block IFN-β production by transcriptional repression via 
interaction with the host protein SAP30 [20,45,46]; it appears that the virulence of a 
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particular RVFV strain does not depend on its interferon sensitivity but rather on its 
ability to block the production of IFN-α/β [43]. Next, it interferes with basal 
transcription factor TFIIH: although the virus replicates in the host cell cytoplasm, NSs 
forms a ribbon-like filamentous structure in the host cell nucleus which sequesters the 
p44 subunit of the TFIIH complex. This then prevents assembly and action of the TFIIH 
complex in the cell. By this mechanism, NSs begins to inhibit general transcription in 
infected cells by 8 hours post-infection [20,45,47-51]. Finally, NSs targets and 
specifically triggers degradation of the antiviral, IFN-induced, dsRNA-dependent protein 
kinase R (PKR), a serine-threonine kinase activated by viral RNAs which mediates 
translational suppression by preventing the phosphorylation of eukaryotic initiation 
factor 2 alpha (eIF2α) [20,52-55]. Mice expressing PKR are capable of clearing infection 
of attenuated RVF virus Clone 13, which has a defective NSs gene due to a large in-
frame deletion, but knockout mice lacking PKR (thereby mimicking the conditions of 
infection with a functional NSs protein) are unable to do so [52]. Thus, NSs has multiple 
functions to counteract the host interferon response and to prevent the production of 
antiviral proteins at both transcriptional and translational levels. Interestingly, NSs also 
targets and interacts with specific DNA regions of the host genome, an action which is 
correlated with the induction of chromosome cohesion and segregation defects in 
RVFV-infected murine and ovine cells. It has been postulated that an accumulation of 
such defects during embryonic development might be partly responsible for the fetal 
deformities and abortions observed in RVFV-infected animals [56]. 
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Pathogenesis and Host Immune Response 
The pathogenesis of RVFV after natural transmission is likely similar to that of 
other arboviruses and thus involves the virus being transported from the initial infection 
site to lymph nodes via the lymphatic system. Early viral replication occurs in the lymph 
nodes, and the virus then spreads through the bloodstream, resulting in primary viremia 
and subsequent infection of target organs. Major sites of viral replication include the 
liver, spleen, and, in animals that succumb to encephalitis, the brain [57,58]. The 
principal site of RVF-induced lesions is the liver in both human and animal hosts; this 
organ is clearly an early and dominant target of the virus. However, during severe 
infections, virus can be found in virtually all tissues and cell types, indicating a likely 
ubiquitous cellular receptor for the virus [20,59]. 
Infection with RVFV is regulated by interferons and terminated by neutralizing 
antibodies (NA). The lytic virus-cell interaction observed with RVFV suggests that its 
major effects are due to direct, virus-induced necrosis, particularly in the liver, by the 
destruction of infected cells [60]. Virus maturation typically occurs within Golgi vesicles 
with subsequent exocytosis; therefore, it was originally proposed that cells infected with 
phleboviruses such as RVFV did not express cell-surface antigens [61]. According to 
further studies, however, in certain virus-cell combinations, morphogenesis of RVFV 
progresses by budding from the plasma membrane, thus resulting in the cell membrane 
bearing viral antigens [62]. Regardless, RVFV infection usually does not result in 
significant expression of cell-surface viral antigens, and as such, infected cells are not 
targeted for elimination by cytotoxic T lymphocytes. Thus, the organism is not rescued 
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from RVFV infection by the processes of cell-mediated immunity. Rather, neutralizing 
antibodies appear to be the primary host response involved in recovery; therefore, 
humoral adaptive immunity is responsible for survival of infection with RVFV [60]. A 
strong innate immune response to restrain initial virus replication and dissemination is 
crucial for survival of the host and must be followed by a robust adaptive immune 
response. Detectable levels of NA are produced within 4-8 days after infection and are 
primarily directed against the viral glycoproteins Gn and Gc; these are followed by IgM 
and IgG antibodies targeting the nucleoprotein N and the non-structural protein NSs 
[20,63-67]. In studies with rhesus macaques, which present clinical disease symptoms 
similar to humans in response to RVFV infection, significant viremia (as well as 
abnormal liver function) was observed in all subjects, both survivors and mortalities, and 
the severity of the disease corresponded to the extent and persistence of viremia. The 
appearance of NA in surviving monkeys coincided with termination of viremia [68]; 
furthermore, passive immunization had previously proven highly effective as a means of 
prophylaxis [69]. The high viral titers observed in lymphoid tissues may explain the 
inability of the majority of fatally infected macaques to mount a serum antibody 
response [60,69]. Rodent models support the concept that antibodies play a dominant 
role in recovery from RVFV, as fatal disease can be prevented in immunosuppressed rats 
by the administration of sufficient quantities of antibody to mimic the titers of serum NA 
that naturally develop in intact, infected animals [70]. Disease can similarly be prevented 
or treated with antibody in mice [71,72], implicating neutralizing antibodies as the 
decisive component in the primary and continuing protection of infected animals and 
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also therefore as an appropriate measure of the level of protection conferred by vaccines 
[20,68,73]. 
Interferon (IFN) has also proven extremely important in determining the fate of 
infected rodents and monkeys. A type of cytokine made and released by lymphocytes 
and other interferon-producing cells (IPCs), also known as plasmacytoid dendritic cells, 
as part of the innate immune system, interferon interrupts viral replication within host 
cells and also induces transcription of certain genes, creating an antiviral state in target 
cells. In the previously cited studies in rhesus macaques, there was a noticeable 
correlation observed between a delayed interferon response and death. Serum interferon 
appeared significantly earlier in surviving monkeys, while those that died had transient 
and low-level serum interferon, indicating a failure to limit virus replication and to 
establish an effective antiviral state. This suggests that the early appearance of serum 
IFN (within the first 24 hours of infection) is critical for limiting the severity of disease 
[68]. Additionally, the therapeutic administration of IFN-α in rhesus monkeys beginning 
24 hours before RVFV inoculation either prevents or greatly diminishes viremia and 
clinical disease [74]. The virus also has proven sensitive to IFN-α in vitro, and multiple 
studies indicate the importance of interferon along with serum antibody in determining 
the outcome of both simian and rodent infections with RVFV in vivo [68,72-76]. In 
particular, RVFV has been shown to be sensitive to murine interferon in vitro, and in 
various in vivo studies, administration of interferon inducer poly(ICLC) within 24 hours 
of virus infection has resulted in virtually complete protection of RVFV-infected mice 
and hamsters [72,77]. Additionally, knockout mice lacking the β-subunit of the IFN-α/β 
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receptor are highly susceptible to attenuated strains of RVFV [78]. Multiple studies also 
indicate that interferon plays a crucial role in resistance to RVFV in rats. Sensitivity of 
the particular RVFV strain to interferon has been found to be a major determining factor 
in the recovery of infected rats [79]. Stimulation with IFN type I in vitro prior to 
infection inhibits RVFV replication in otherwise permissive peritoneal macrophages 
obtained from RVFV-resistant LEW/NHsdBR rats; however, the same effect cannot be 
achieved by interferon stimulation in the macrophages of RVFV-susceptible WF/HsdBR 
rats [80,81]. Additionally, injection of anti-IFN type I antibodies into RVFV-resistant 
LEW/Mai rats produces a marked increase in sensitivity to RVFV, while treatment of 
susceptible WF/Mai rats with interferon increases the likelihood of surviving infection 
with the virus [82]. Furthermore, studies involving cytoplasmic Mx proteins in humans 
and in rats have produced evidence of RVFV sensitivity to these IFN-induced antiviral 
GTPases. Specifically, the human MxA protein has been shown to inhibit early RVFV 
viral replication [83], and the Mx2 protein exhibited similar inhibition of RVFV in 
cotton rats [84] and laboratory rats [85]. Thus, a strong and immediate innate immune 
system interferon response to restrict initial viral replication and dissemination, 
accompanied by a prompt and robust adaptive immune response with the production of 
neutralizing antibodies, is critical for host survival of RVFV infection. However, it is 
acknowledged that further detailed study of the host innate, humoral, and cell-mediated 
immune pathways is necessary to attain a comprehensive knowledge of RVFV 
immunology [20]. 
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Virus Transmission 
RVF virus is primarily transmitted between animals by a wide array of arthropod 
vectors, including ticks, biting midges, hematophagous flies, and especially mosquitoes 
[2,3]. The accepted transmission method involves transovarial transmission of RVFV in 
certain Aedes species (spp.) of mosquitoes via their eggs, which can withstand 
desiccation and serve as reservoirs during periods of drought [86,87]. After rainfall and 
flooding, biological transmission occurs near water sources from vectors to bovid hosts 
via infected mosquito saliva. If flooding remains for 2-3 weeks, Culex spp. mosquitoes 
succeed the Aedes spp. in a population explosion [88] and become infected from feeding 
on nearby viremic bovids. Culex spp. are more likely to disperse in search of vertebrate 
hosts than Aedes spp., leading to dissemination of the virus and potentially resulting in 
epidemics [20,89]. For this reason, outbreaks of RVF tend to coincide with an increase 
in mosquito breeding grounds due to events such as the building of dams or to periods of 
heavy rainfall and flooding [58]. RVFV can also be transmitted transcutaneously 
through direct contact with infected animals, tissues, carcasses, or bodily fluids, and by 
aerosolization and inhalation; these methods are the greatest concern for human infection 
[2,90]. 
 
RVF Disease, Threat Risk, and Current Countermeasures 
Of the numerous significant outbreaks of RVF over the years, the extensive 
epidemic that occurred in the Nile Delta of Egypt in 1977 is particularly noteworthy as it 
was when the four distinct manifestations of the disease in humans were first recorded. 
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The vast majority of infected humans suffer only mild, flu-like symptoms which last 4-7 
days, but in a small percentage of cases, the disease becomes more severe. Ocular 
disease, taking the form of retinal lesions which appear 1-3 weeks after initial symptoms, 
occurs in 0.5-2% of cases and may result in permanent loss of vision. 
Meningoencephalitis occurs in less than 1% of cases; within 1-4 weeks after initial 
symptoms comes the onset of headache, memory loss, confusion, hallucinations, and 
possibly coma. Sufferers of this form of disease may have lasting neurological 
complications. The final and most deadly form of the disease is hemorrhagic fever. 
Occurring in less than 1% of cases, about 2-4 days after initial symptoms, jaundice and 
signs of hemorrhaging begin to appear. The case-fatality ratio for this form is 
approximately 50% and usually occurs within 3-6 days of the onset of symptoms 
[2,91,92]. 
The severity of RVF is strongly age-dependent, with resistance increasing with 
age. General symptoms include fever, loss of appetite, jaundice, and weakness; the 
disease often causes fulminant hepatitis with high mortality rates and nearly 100% 
abortion rates (termed “abortion storms”) in domestic ruminant herds, especially those of 
European origin, which are more susceptible than native African stock [2,20,35,93]. This 
makes RVF a disease of great economic and agricultural concern to the USA as it 
presents a frighteningly devastating potential weapon of bioterrorism, particularly due to 
its ability to infect humans as well as livestock. This threat has been recognized by the 
Centers for Disease Control and Prevention, the United States Department of Health and 
Human Services, and the United States Department of Agriculture, who have classified 
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the virus as a select agent [94]. Additionally, it is one of the three primary animal 
diseases being focused on by the Department of Homeland Security’s Institute for 
Infectious Animal Diseases (IIAD) due to posing “significant risks to public health or 
the national economy” [95]. Vaccines exist, in both attenuated [96,97] and inactivated 
[98] forms, which have been approved for use in both humans and animals but which are 
not optimally efficacious. The inactivated vaccine is not as effective as the attenuated 
forms, requiring multiple inoculations and providing only low levels of protection [99]. 
Two attenuated forms, MP12 and clone 13, have been developed which have mutations 
in the NSs gene and thus are excellent inducers of early IFN-α/β production 
[43,96,97,100]. Trials of the attenuated MP12 variant in young lambs, pregnant ewes, 
fetal and neonatal bovids, and cattle proved promising [63-65,101,102], and additionally, 
the vaccine induced a good immunity in rhesus macaques and showed potential as a 
candidate for human vaccination; however, concurrent neurovirulence testing in the 
macaque trials indicated that the vaccine is not completely innocuous [103]. 
Additionally, MP12 trials in South Africa resulted in some abortions and teratogenesis 
during early pregnancy in ewes [104]. The naturally attenuated Clone 13 viral variant, 
containing a deletion in the S segment coding for the NSs protein and thus incapable of 
reverting, is another promising prospect. In trials carried out in sheep and cattle, no 
deleterious effects or abortions were observed in pregnant ewes, and the vaccine elicited 
a high antibody response resulting in protection against a virulent challenge [20,97]. 
However, there is currently no real established course of treatment for infection, and it 
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would be advantageous to develop additional, less conventional options for protection 
against the potentially disastrous consequences of a threat such as RVF. 
 
RVF and Inbred Rat Strains 
Animal models are a necessity for studying this RVF disease. Current models 
range from ruminants (sheep, goats, and cattle) to rodent laboratory animals (mice, rats, 
hamsters, and gerbils) to non-human primates such as rhesus macaques [20,105,106]. 
The mouse model of RVF disease simulates both the acute-onset hepatitis and the 
delayed-onset encephalitis seen in human infection, and recognition of the need for a 
well-characterized small animal model of RVF infection has prompted recent detailed 
studies examining RVFV in the mouse model [35,107]. As a small animal model 
species, the laboratory rat (Rattus norvegicus) is particularly valuable because it either 
demonstrates resistance (exhibiting an immunizing infection with no obvious symptoms 
of illness), develops hepatitis, or develops fatal encephalitis, mimicking characteristic 
responses of both humans and livestock to the disease [76]. Thus, the rat provides a 
useful model for study, and it is additionally the only species for which inbred strains 
exist which are either naturally resistant or susceptible to RVF hepatic disease [70]. This 
hepatic disease is the focus of this particular study. In a previous report, differential 
pathogenesis of RVFV was found between the Wistar Furth (WF) and Lewis (LEW) 
inbred rat strains due to genetic differences between the strains. The disease was found 
to progress quickly in WF rats, with all subjects dead from fatal liver necrosis by day 2 
post-inoculation. LEW rats, on the other hand, showed resistance to liver disease, 
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resulting in an 84% survival rate, with the other 16% developing fatal necrotizing 
encephalitis 2-3 weeks post-inoculation. Further examination showed that viral 
replication progressed rapidly in WF, causing extensive organ damage before the body 
could mount an effective immune response. By contrast, LEW rats were better able to 
restrict initial virus growth and replication, thus allowing the body time to mount an 
antibody response able to control and terminate the infection [70]. Classical genetic 
studies showed that the LEW resistant phenotype was controlled by a single dominant 
gene (or possibly a closely linked gene complex) inherited in classic Mendelian fashion 
[79]. Subsequently, a WF.LEW congenic strain was developed by backcrossing the 
resistant LEW genome (using the LEW/Mai substrain as the donor strain) onto the 
susceptible WF background (using the WF/Mai substrain as the recipient strain) with 
selection at each generation for resistance to RVF [108]. However, studies later appeared 
reporting results which conflicted with those that formed the basis for the creation of this 
congenic strain. These studies found that, conversely, WF rats of the WF/Mol substrain 
were resistant to RVFV infection and that LEW rats of the LEW/Mol substrain were 
susceptible. Additionally, while the resistance of the WF/Mol rats also segregated as a 
single dominant gene, it did not appear to depend on an interferon response [109] as had 
been previously described in rat models [79-82,85]. Subsequently, a complete genome 
comparison of the LEW/Ztm and LEW/Mol substrains using SSLP markers with a 
minimum of three markers per chromosome revealed the introduction of approximately 
37% non-LEW genome into the LEW/Mol substrain [110]. These conflicting data were 
further reconciled by a comprehensive genomic comparison of five commercially 
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available LEW and WF substrains using microsatellite markers [111]. According to 159 
SSLPs spanning the entire rat genome with a minimum of four markers per 
chromosome, the LEW/MolTac substrain showed approximately 37% difference from 
the LEW/SsNHsd substrain and approximately 45% difference from the LEW/Crl 
substrain while the LEW/SsNHsd and LEW/Crl substrains demonstrated only an 
approximately 8% difference from each other. The two WF substrains examined, 
WF/NHsd and WF/CrCrl, similarly demonstrated an approximately 8% difference 
between them. This study not only offered an explanation for the striking differences in 
resistance and susceptibility seen in the LEW/Mol rat substrain when compared to other 
substrains [109,110] but also served as a reminder of the importance of utilizing inbred 
strains from a single source when possible [111]. 
Efforts were then initiated to further investigate the source of the natural 
resistance exhibited by the WF.LEW strain. As the original LEW/Mai and WF/Mai 
parental substrains were extinct, an initial genome scan of 137 SSLP markers was 
performed and compared to the five WF and LEW substrains previously investigated 
[111] in order to characterize the genome of the congenic strain. LEW markers were 
identified on Rattus norvegicus chromosomes 3 (RNO3) and 9 (RNO9). Those regions 
were then further characterized in the congenic strain and the five other substrains by an 
additional 15 SSLP markers and 24 SNP markers on RNO3 and an additional 7 SSLP 
markers and 8 SNP markers on RNO9 [112]. In total, 5 SNP markers and 3 SSLP 
markers defined an approximately 1.8Mb LEW region on RNO3 while only 1 SSLP 
LEW marker was discovered on RNO9. Clearly, further study was required to determine 
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the responsible gene, discover the mechanism by which it confers resistance to RVF, and 
investigate beneficial future applications of that knowledge. 
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CHAPTER II 
CHARACTERIZATION AND IDENTIFICATION OF THE CHROMOSOME OF 
INTEREST 
 
Introduction 
 The first objective to be accomplished was to determine whether RNO3 or RNO9 
contained the location of the primary agent of resistance, or alternatively, if the regions 
on both chromosomes were required to achieve the effect. In order to reach this 
conclusion, the first step taken was to test an additional 13 SNP markers and 5 SSLP 
markers from the distal end of RNO3 and compare them across 6 different rat substrains: 
LEW/SsNHsd, LEW/Crl, WF.LEW, LEW/MolTac, WF/NHsd, and WF/Crl. 
(Appendices A and B contain the list of the specific RNO3 SSLP and SNP markers, 
respectively, and their corresponding alleles for each strain.) This resulted in the 
identification of 6 supplementary differential SNP markers, more precisely defining the 
region of interest (ROI) on that chromosome and increasing the total number of 
differential markers for the RNO3 region to 14, consisting of 11 SNPs and 3 SSLPs (Fig. 
1 and Fig. 2). 
Meanwhile, a breeding plan was organized to generate N1 offspring from the 
WF.LEW rats which could be used to contrast the RNO3 and RNO9 regions via viral 
challenge. To produce the N1 offspring, a susceptible inbred strain was needed to 
backcross with the resistant WF.LEW. Unfortunately, the colonies of WF/Mai and  
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Fig. 1 RNO3 SSLP and SNP marker locations and alleles for six substrains. 
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Fig. 2 RNO9 SSLP and SNP marker locations and alleles for six substrains. 
 
LEW/Mai rats, the original substrains used to create the congenic strain, had been 
discontinued, and thus those substrains were extinct. However, the LEW/SsNHsd and 
WF/NHsd rat substrains may have been derived from similar source colonies as the 
 18 
 
 
LEW/Mai and WF/Mai rats, respectively, and are postulated to be the most closely 
related extant substrains to the defunct LEW/Mai and WF/Mai substrains [111]. Results 
of the previous investigation comparing the DNA of WF.LEW rats to that of five inbred 
substrains using 137 SSLP markers supported this claim, as the Harlan substrains shared 
the most markers in common with the congenic strain [112]. As such, for all breeding 
and challenge purposes, the LEW/SsNHsd and WF/NHsd rat substrains were utilized in 
conjunction with the WF.LEW rats in lieu of the original founding LEW/Mai and 
WF/Mai substrains. Accordingly, to generate N1 rats, resistant WF.LEW rats were 
crossed with susceptible WF/NHsd rats, resulting in F1 hybrids which were then 
backcrossed to WF/NHsd rats to produce the N1 generation. Once a sufficient number of 
N1 offspring had been generated, each one was characterized by the previously 
established differential markers (14 on RNO3 and 1 on RNO9) in order to segregate 
them into four genotypic groups: those showing no LEW markers; those showing LEW 
markers on RNO3 only; those showing LEW markers on RNO9 only; and those showing 
LEW markers on both RNO3 and RNO9 (Fig. 3). Eventually, 25 N1 rats collected from 
three separate litters, along with positive and negative control rats of various inbred 
strains, were challenged with RVFV to establish and verify the phenotype corresponding 
to each genotype. 
 
Materials and Methods 
 Previously, live WF.LEW rats were re-derived by the Rat Resource and Research 
Center (RRRC) at the University of Missouri (Columbia, MO) from frozen embryos that 
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had been maintained at the National Institutes of Health (NIH), and breeding pairs were 
sent to Texas A&M University (College Station, TX) to found a colony. Once 
established, WF.LEW female rats were mated with WF/NHsd male rats purchased from 
Harlan (Indianapolis, IN) to produce (WF.LEW x WF/NHsd)F1s. Female F1s were then  
 
 
 
Fig. 3 Representation of RNO3 and RNO9 chromosome pairs of the four N1 genotypic groups. Red 
denotes WF genome (from WF/NHsd or WF/Mai recipient strain of WF.LEW); green denotes LEW 
genome (from LEW/Mai donor strain of WF.LEW).  
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backcrossed to WF/NHsd males to produce an N1 generation of (WF.LEW x 
WF/NHsd)F1 x WF/NHsd rats. Rats were housed on Texas A&M University campus in 
the Laboratory Animal Resources and Research Facility (LARR), accredited by the 
Association for the Assessment and Accreditation of Laboratory Animal Care, 
International (AAALAC). Animals were maintained according to the Animal Use 
Protocol (AUP) filed with the TAMU Office of Research Compliance under the Animal 
Welfare Assurance Program (AWAP) and approved by the Institutional Animal Care 
and Use Committees (IACUC). 
Genomic DNA for initial SSLP and SNP marker testing of the six strains had 
previously been extracted from rat spleen tissue by phenol extraction with ethanol 
precipitation [113]. Genomic DNA of N1 rats was extracted from 0.2cm tail snips, 
collected humanely from neonates, by a previously described HotSHOT protocol [114], 
using a 30min heating time in a TC-512 (Techne, Minneapolis, MN) thermal cycler. 
SSLPs and SNPs were selected using the Genome Browser of the Rat Genome 
Database (RGD) v3.4 Assembly [115]. Established primers cited on RGD were used for 
SSLPs; SNP forward and reverse primers were designed using Primer3 (v. 0.4.0) [116]. 
Each specific SNaPshot primer consisted of the 30 bases immediately 5’ to the SNP 
location according to RGD v3.4. A previously described method utilizing M13-tailed 
primers was used to streamline genotyping by SSLP markers [117]. Each forward SSLP 
primer was created with a 5’-tail of the M13 sequence. Additionally, M13 sequence 
primers were synthesized with a 5’ label of either 6-FAM, HEX, or NED (Applied 
Biosystems, Foster City, CA). For the forward primer component of each reaction, a 
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mixture of the M13-tailed forward SSLP primer with a fluorescent-labeled M13 primer 
in a 1:15 ratio was used. Each SSLP was amplified by standard polymerase chain 
reaction (PCR) [118]. Each reaction consisted of 1µl 10x PCR Buffer with 15mM MgCl2 
(Applied Biosystems), 0.5U AmpliTaq Gold® DNA Polymerase (Applied Biosystems), 
200µM each dNTP, 250nM each forward and reverse primer, 100ng genomic DNA, and 
Q.S. of double-distilled water to produce a 10µl reaction. Thermal cycling parameters 
were set as follows: initialization at 94ºC for 10min, followed by 35 cycles of 
denaturation at 94ºC for 30s, annealing at 58ºC for 30s, and extension at 72ºC for 30s, 
and ending with a final extension at 72ºC for 5min. SNPs were genotyped utilizing the 
SNaPshot® Multiplex Kit (Applied Biosystems). The initial PCR reaction contained 1µl 
10x PCR Buffer with 15mM MgCl2 (Applied Biosystems), 0.5U AmpliTaq Gold DNA 
Polymerase (Applied Biosystems), 200µM each dNTP, 250nM each forward and reverse 
primer, 100ng genomic DNA, and Q.S. of double-distilled water to produce a 10µl 
reaction. Thermal cycling conditions were set as follows: initialization at 94ºC for 
10min, followed by 35 cycles of denaturation at 94ºC for 30s, annealing at 60ºC for 30s, 
and extension at 72ºC for 30s, and ending with a final extension at 72ºC for 5min. 
Postreaction products were subsequently purified using the QIAquick® PCR 
Purification Kit (Qiagen, Valencia, CA) according to the manufacturer’s recommended 
protocol, adding 20µl of double-distilled water to elute in the final step. The ensuing 
SNaPshot reactions consisted of 3µl of purified PCR product, 2µl of SNaPshot 
Multiplex Ready Reaction Mix, 500nM SNaPshot primer, and the necessary amount of 
double-distilled water to yield a 10µl reaction. Thermal cycling parameters for the 
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SNaPshot reaction and following post-extension treatment with 1.0 Unit of Shrimp 
Alkaline Phosphatase (SAP) were set according to the manufacturer’s instructions. All 
PCR and SNaPshot reactions were performed using either a TC-512 (Techne) or a 
GeneAmp PCR System 9700 (Applied Biosystems) thermal cycler. Final reaction 
products of both SSLP and SNaPshot reactions were analyzed using a 3130xl Genetic 
Analyzer (Applied Biosystems), and genotypes were visualized using GeneMapper® 
version 4.0 (Applied Biosystems) and exported to a spreadsheet for organization and 
comparison (Excel, Microsoft, Redmond, WA). 
 All viral challenge work was performed in ABSL-4 containment at the 
University of Texas Medical Branch in Galveston, Texas. Groups of adult rats 10 weeks 
of age or older were inoculated subcutaneously with 0.1ml of 5x10
5
 ZH501 strain of 
RVFV for the experimental groups or with 0.1ml Hank’s Balanced Salt Solution (HBSS) 
diluent for control animals. Commercially available inbred strains tested included 
LEW/SsNHsd and WF/NHsd, purchased from Harlan (Indianapolis, IN), LEW/MolTac, 
purchased from Taconic (Germantown, NY), and LEW/Crl and WF/CrCrl, purchased 
from Charles River Laboratories (Boston, MA). Additionally, WF.LEW rats, (WF.LEW 
x WF/NHsd)F1 hybrids, and their (WF.LEW x WF/NHSd)F1 x WF/NHsd N1 backcross 
offspring, obtained and produced by the previously described methods, were also 
challenged. All animals were properly transported and handled in accordance with the 
guidelines of the Animal Use Protocol (AUP) referenced above. Survival was compared 
by the log-rank test, and all statistical analyses were conducted using the GraphPad 
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Prism 6.0 software (GraphPad, La Jolla, CA). Differences in survival were considered to 
be significant at P < 0.05. 
 
 
Results and Discussion 
 The results of the challenge showed a statistically significant difference (P < 
0.0001) in survival among the four groups and clearly implicated the approximately 
1.8Mb LEW region on the distal end of RNO3 as containing the major gene responsible 
for resistance to RVFV, with N1 rats possessing only the region on RNO9 surviving 
only slightly longer than susceptible rats lacking both regions (Table 1, Fig. 4). 
Interestingly, rats containing the LEW region of both RNO3 and RNO9 had a 100% 
survival rate, compared to a 75% survival rate for rats containing the LEW region on 
RNO3 only. However, these results were reasonably congruous with previous findings 
of a LEW survival rate of 84% with death delayed until the second week post-infection 
[70]. Thus, while possible contributions of the LEW region of RNO9 to resistance in a 
supporting capacity could not be ruled out, it was the LEW region on RNO3 which was 
discovered to merit further investigation. 
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Table 1 Viral challenge survival: N1s, plus assorted inbred strains 
Strain / Group Identification Inoculated Survived Percent Survival 
WF/NHsd 5 0 0% 
WF/CrCrl 5 0 0% 
LEW/MolTac 5 0 0% 
LEW/SsNHsd 5 2 40% 
LEW/Crl 5 4 80% 
WF.LEW 5 4 80% 
(WF.LEWxWF/NHsd)F1 5 4 80% 
N1: No LEW genome 6 0 0% 
N1: LEW genome RNO3 only 8 6 75% 
N1: LEW genome RNO9 only 6 0 0% 
N1: LEW genome RNO3 
       and RNO9 
5 5 100% 
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Fig. 4 N1 survival of RVF viral challenge. From a minimum of five rats from each group challenged with 
0.1ml of 5x105 ZH501 strain of RVFV. P < 0.0001. All surviving rats were humanely euthanized on day 
28. 
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CHAPTER III 
ISOLATION AND DEFINITION OF THE CHROMOSOMAL REGION OF 
INTEREST 
 
Introduction 
 With the LEW region on RNO3 having been established as the primary region of 
interest for conferring resistance to RVFV, the next step in seeking out the responsible 
gene was to narrow this ~1.8Mb region to a more practicable size for further 
investigation. This was proposed to be accomplished mainly through continued 
backcrossing of F1 hybrids of WF.LEW rats and WF/NHsd rats to WF/NHsd rats, with 
subsequent genotyping of the N1 offspring using the 14 previously established 
differential markers in order to identify any recombination within the LEW region. With 
a reported recombination rate of 0.55cM/Mb for RNO3 [119], the expectation was that 
approximately 1 in 100 N1 rats produced would exhibit recombination within the 
~1.8Mb region. The first recombinant rat generated happened to be an offspring from a 
unique pairing of two N1 rats previously produced and genotyped as containing the 
LEW region on RNO3 only but not used for the earlier referenced RVFV challenges. 
This male offspring showed recombination between microsatellite D3Rat1 and SNP 
marker rs8164532, thus retaining the LEW genome only in the approximate upper half 
of the ROI (~0.9Mb) (Fig. 5). The recombinant rat furthermore showed from genotyping 
to have received the entire ~1.8Mb RNO3 LEW region from one parent and the 
recombined approximate half of the RNO3 LEW region from the other parent; thus, this  
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Fig. 5 Genotype of first recombinant rat for RNO3. 
 
male recombinant was backcrossed to WF/NHsd females, and the R1 (first recombinant 
generation) offspring were genotyped to determine which approximate half of the 
offspring exhibited the full ~1.8Mb LEW region and which contained the smaller, 
recombined ~0.9Mb LEW region. Those with the recombined LEW region were 
considered of interest and were subsequently challenged with RVFV. Incidentally, one 
of these R1 offspring indicated the occurrence of a second recombination event between 
SNP marker rs8156398 and microsatellite D3UIA3, thus gaining back an additional  
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Fig. 6 Genotype of second recombinant rat for RNO3. 
 
~0.5Mb of LEW region as compared to the original recombinant (Fig. 6). This second 
male recombinant was accordingly bred to female WF/NHsd rats, the offspring were 
genotyped to determine which contained the second recombination event, and 
appropriate representatives were then challenged with RVFV in order to further isolate 
and define a smaller region of interest on RNO3. 
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Materials and Methods 
 Previously established (WF.LEW x WF/NHsd)F1 rats were mated with 
WF/NHsd rats purchased from Harlan to produce additional (WF.LEW x WF/NHSd)F1 
x WF/NHsd N1 backcross offspring. One N2 litter from a N1 x N1 cross was also 
produced. Rats were housed at LARR and maintained in accordance with the AUP 
previously referenced. 
 As before, 0.2cm tail snips, collected humanely from neonates, were used to 
obtain genomic DNA from N1 and N2 rats by extraction according to the previously 
referenced HotSHOT protocol [114] with a 30min heating time in a TC-512 (Techne) 
thermal cycler. The previously established SSLPs were amplified by standard PCR [118] 
using M13-tailed primers [117] as previously described. Each reaction consisted of 1µl 
10x PCR Buffer with 15mM MgCl2 (Applied Biosystems), 0.5U AmpliTaq Gold DNA 
Polymerase (Applied Biosystems), 200µM each dNTP, 250nM each forward and reverse 
primer, 100ng genomic DNA, and Q.S. of double-distilled water to produce a 10µl 
reaction. Thermal cycling parameters were set as follows: initialization at 94ºC for 
10min, followed by 35 cycles of denaturation at 94ºC for 30s, annealing at 58ºC for 30s, 
and extension at 72ºC for 30s, and ending with a final extension at 72ºC for 5min. As 
before, the previously established SNPs were genotyped utilizing the SNaPshot 
Multiplex Kit (Applied Biosystems). The initial PCR reaction contained 1µl 10x PCR 
Buffer with 15mM MgCl2 (Applied Biosystems), 0.5U AmpliTaq Gold DNA 
Polymerase (Applied Biosystems), 200µM each dNTP, 250nM each forward and reverse 
primer, 100ng genomic DNA, and Q.S. of double-distilled water to produce a 10µl 
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reaction. Thermal cycling conditions were set as follows: initialization at 94ºC for 
10min, followed by 35 cycles of denaturation at 94ºC for 30s, annealing at 60ºC for 30s, 
and extension at 72ºC for 30s, and ending with a final extension at 72ºC for 5min. 
Postreaction products were subsequently purified using the QIAquick PCR Purification 
Kit (Qiagen) according to the manufacturer’s recommended protocol, adding 20µl of 
double-distilled water to elute in the final step. The ensuing SNaPshot reactions 
consisted of 3µl of purified PCR product, 2µl of SNaPshot Multiplex Ready Reaction 
Mix, 500nM SNaPshot primer, and the necessary amount of double-distilled water to 
yield a 10µl reaction. Thermal cycling parameters for the SNaPshot reaction and 
following post-extension treatment with 1.0 Unit of Shrimp Alkaline Phosphatase (SAP) 
were set according to the manufacturer’s instructions. All PCR and SNaPshot reactions 
were performed using either a TC-512 (Techne) or a GeneAmp PCR System 9700 
(Applied Biosystems) thermal cycler. As previously, final reaction products of both 
SSLP and SNaPshot reactions were analyzed using a 3130xl Genetic Analyzer (Applied 
Biosystems), and genotypes were visualized using GeneMapper version 4.0 (Applied 
Biosystems) and exported to a spreadsheet for organization and comparison (Excel, 
Microsoft). 
 All viral challenge work was carried out in ABSL-4 containment at the 
University of Texas Medical Branch in Galveston, Texas. To test the resistance status of 
the two recombinants, offspring were produced by mating each recombinant male rat 
with female WF/NHsd rats. Those offspring which retained the respective recombined 
paternal RNO3 were challenged at a minimum of 10 weeks of age by subcutaneous 
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inoculation with 0.1ml of 2x10
5
 ZH501 strain of RVFV for the experimental groups of 
the first recombinant and 0.1ml 1x10
5
 ZH501 strain of RVFV for the experimental 
groups of the second recombinant, or with 0.1ml Hank’s Balanced Salt Solution (HBSS) 
diluent for control animals. Additionally, WF.LEW rats, WF/NHsd rats, and littermates 
of the recombinants which were determined to be heterozygous for the full ROI on 
RNO3 (genetically identical to (WF.LEW x WF/NHsd)F1 hybrids), all of which were 
obtained, maintained, or produced from the previously explained sources or by the 
previously described methods, were also challenged under these conditions. All animals 
were appropriately transported and handled in accordance with the guidelines of the 
Animal Use Protocol (AUP) referenced above. Survival comparison by the log-rank test 
was performed using the GraphPad Prism 6.0 software (GraphPad). Differences in 
survival were considered to be significant at P < 0.05. 
 
Results and Discussion 
 As can be seen in Table 2 and Fig. 7, results for each recombinant were clear and 
consistent, and furthermore were determined to be statistically significantly different (P 
< 0.01): all rats containing the first recombination event died within 48 hours post- 
inoculation, in keeping with previous results from susceptible rats, while the group 
retaining the second recombination event had an 80% survival rate with the single non- 
surviving subject lasting nearly a week post-inoculation, as has been seen previously in 
resistant rats [70]. As such, the region of interest was now determined to be limited to 
the ~0.5Mb area between microsatellites D3Rat1 and D3UIA3. This new ROI, 
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containing a total of 20 genes (including the two genes containing D3Rat1 and D3UIA3, 
respectively) was considered to be a reasonable size for further investigation in the form 
of qPCR experiments and sequencing comparisons between the resistant WF.LEW and 
the susceptible WF/NHsd strains. 
 
Table 2 Viral challenge survival: Recombinants #1 and #2, plus controls 
Strain / Group Identification Inoculated Survived Percent Survival 
WF/NHsd 5 0 0% 
WF.LEW 7 7 100% 
Heterozygote (F1) 3 2 67% 
Recombinant #1 3 0 0% 
Recombinant #2 5 4 80% 
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Fig. 7 Recombinant survival of RVF viral challenge. Based on a minimum of three rats per group 
challenged with 0.1ml of either 2x105 or 1x105 ZH501 strain of RVFV. P < 0.01. All surviving rats were 
humanely euthanized on day 28. 
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CHAPTER IV 
HOMOLOGY OF THE REGION OF INTEREST ACROSS RELEVANT 
SPECIES 
 
Introduction 
 Before embarking on the qPCR and sequencing experiments, a brief further 
exploration and genomic comparison of the newly defined ROI among pertinent species 
was conducted. The species considered particularly relevant to this RVF study included 
Mus musculus as a model organism closely related to the rat, Bos taurus representing 
susceptible and at-risk agriculturally important livestock species, and Homo sapiens due 
to the zoonotic nature of the virus. 
 
Materials and Methods 
 Thorough characterization of the ROI in Rattus norvegicus was established using 
the Rat Genome Database (RGD) v3.4 Assembly [115]. Subsequent investigation of the 
corresponding ROI in each relevant species was carried out using the genome resources 
of the National Center for Biotechnology Information (NCBI) [120] and the University 
of California, Santa Cruz (UCSC) Genome Bioinformatics Site [121]. Assemblies used 
included GRCm38 for Mus musculus, BTAU 4.6.1 for Bos taurus, and GRCh37 for 
Homo sapiens. 
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Results and Discussion 
The ROI proved to be fairly well conserved across all four species. The 
corresponding region of RNO3 mapped to the distal end of mouse chromosome MMU2, 
to the central area of bovine chromosome BTA13, and to the distal end of human 
chromosome HSA20 (Fig. 8). Based on RGD, the final ROI in the rat contained 20 
genes: Ythdf1, Birc7, Nkain4, Arfgap1, Col20a1, Chrna4, Kcnq2, Eef1a2, Ppdpf, Ptk6, 
Srms, RGD1564340, Helz2, Gmeb2, Stmn3, Rtel1, Arfrp1, Zgpat, Lime1, and Zbtb46. 
All of these genes, with the exception of RGD1564340, were present in the 
corresponding ROI of Mus musculus and Homo sapiens; furthermore, according to the 
UCSC Genome Browser, the RGD1564340 sequence matched to the expected position 
(between genes Srms and Helz2) in each of these two genomes as a Non-Mouse or Non-
Human RefSeq Gene, respectively. Meanwhile, the Bos taurus ROI contained 13 of the 
20 genes, with 6 of the remaining 7 genes similarly matching in sequence on the UCSC 
Genome Browser to the expected position in the genome as Non-Cow RefSeq Genes. 
The other gene, Helz2, could not be discovered anywhere in the bovine genome. It was 
also observed that an inversion event involving the ROI seems to have taken place in the 
bovine genome relative to the other three, as the gene order of the entire ROI in the cow 
is reversed compared to that of mouse, human, and rat (Fig. 9). Additionally, the overall 
size of the ROI was smaller in Bos taurus, stretching across ~0.35Mb as compared to the 
approximate 0.55-0.6Mb length of the region in the other three species. While a few 
interposing predicted genes and pseudogenes were found in the ROI in each species, the 
overall consensus of the region was maintained. Thus, the homology of the region 
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appears strong enough for the results of this rat study to prove useful in other species, 
both for additional model species and for endangered target species of the RVF virus. 
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Fig. 8 Relative locations of the homologous ROI among relevant species. Chromosome sizes and region sizes are not to scale. 
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Fig. 9 RNO3 ROI genes present and their arrangement in the corresponding ROI of relevant species. Black type indicates a gene present in the 
species’ genome; gray type indicates the presence of a Non-Species RefSeq Gene on the UCSC Genome Browser. Region sizes are not to scale. 
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CHAPTER V 
ELICITING A PROSPECTIVE GENE AND MECHANISM FOR CONFERRING 
RESISTANCE TO RVF 
 
Introduction 
 To further refine this search down to a single proposed responsible gene or 
mutation, gene expression analysis was carried out by quantitative polymerase chain 
reaction (qPCR) to examine the relative expression levels of the 20 genes in the ROI 
between resistant WF.LEW rats and susceptible WF/NHsd rats under varying 
conditions. Furthermore, in-depth sequencing was performed to compare the resistant 
WF.LEW strain to the susceptible WF/NHsd substrain at the nucleotide level in the 
RNO3 ROI and also to search for larger insertion/deletion events, inversions, and copy 
number variations. The ultimate goal of these experiments was to elucidate a single 
candidate gene or mutation which, upon further investigation, could provide a possible 
mechanism of resistance to be confirmed and reproduced through eventual further study. 
 
Materials and Methods 
 All viral challenge work was carried out in ABSL-4 containment at the 
University of Texas Medical Branch in Galveston, Texas. In total, 9 resistant WF.LEW 
rats and 9 susceptible WF/NHsd rats were challenged after 10 weeks of age by 
subcutaneous inoculation with 0.1ml of 1x10
5
 ZH501 strain of RVFV for infected 
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animals or with 0.1ml Hank’s Balanced Salt Solution (HBSS) diluent for mock-infected 
animals. Rats were sacrificed and livers harvested at the necessary times and conditions 
to obtain 3 samples each for the following categories: mock-infected susceptible rats; 
mock-infected resistant rats; susceptible rats infected for 8hrs; resistant rats infected for 
8hrs; susceptible rats infected for 16hrs; and resistant rats infected for 16hrs. All animals 
were transported and handled in accordance with the guidelines of the Animal Use 
Protocol (AUP) referenced above. 
RNA from rats infected with RVFV was extracted from decontaminated liver 
tissue using the RNAqueous® Kit (Ambion, Austin, TX) according to the manufacturer 
instructions. Additionally, RNA was extracted from fresh liver tissue of one each of 
uninfected WF/NHsd and WF.LEW subjects using the RNeasy® Mini Kit (Qiagen) 
according to the manufacturer’s protocol for “Purification of Total RNA from Animal 
Tissues” using 30ul of RNase-free water to elute in the final step to maximize final RNA 
concentration. All RNA samples were treated with the TURBO DNA-free™ Kit 
(Ambion) according to the “Routine DNase Treatment” protocol to eliminate genomic 
contamination. cDNA synthesis was performed using the SuperScript® III First Strand 
Synthesis System (Invitrogen, Carlsbad, CA) with oligo(dT) primers according to the 
manufacturer’s instructions. RNA samples were stored at -80ºC, and cDNA samples 
were stored at -20ºC. 
 Established TaqMan® Gene Expression Assays (Applied Biosystems) were 
utilized for the qPCR reactions for the 20 genes in the ROI. Assays used were as 
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follows: Clone ID Rn00620538_m1 for Ythdf1; Clone ID Rn01412717_g1 for Birc7; 
Clone ID Rn01754303_m1 for Nkain4; Clone ID Rn00709933_m1 for Arfgap1; Clone 
ID Rn01415880_m1 for Col20a1; Clone ID Rn00577436_m1 for Chrna4; Clone ID 
Rn00591249_m1 for Kcnq2; Clone ID Rn00561973_m1 for Eef1a2; Clone ID 
Rn01416146_g1 for Ppdpf; Clone ID Rn01220413_m1 for Ptk6; Clone ID 
Rn01754314_m1 for Srms; Clone ID Rn01412535_m1 for RGD1564340; Clone ID 
Rn01220411_g1 for Helz2; Clone ID Rn00582564_m1 for Gmeb2; Clone ID 
Rn00456287_m1 for Stmn3; Clone ID Rn01220420_m1 for Rtel1; Clone ID 
Rn01416050_g1 for Arfrp1; Clone ID Rn01412640_m1 for Zgpat; Clone ID 
Rn01416098_g1 for Lime1; and Clone ID Rn01220398_m1 for Zbtb46. After analysis 
of cDNA serial dilutions, a 1:5 dilution was found to be the best across all samples and 
was subsequently used for all qPCR reactions. Additionally, after preliminary 
experimentation, ActB (beta-actin) was determined to be a remarkably consistent 
endogenous control for these experiments and was therefore used for all qPCR runs. 
Three replicates of each of the 20 samples were tested for each of the 20 genes. 10ul 
reactions were prepared using 1.0ul template RNA, 0.5ul of the respective TaqMan Gene 
Expression Assay (20X), 5.0ul TaqMan Gene Expression Master Mix (2X) (Applied 
Biosystems), and 3.5ul RNase-free water (Qiagen) and were run on the 7900HT Fast 
Real-Time PCR System (Applied Biosystems) for 40 cycles on standard mode with 
default settings. Results were exported to a spreadsheet (Excel, Microsoft, Redmond, 
WA) for analysis. Relative quantitation of qPCR results was performed according to the 
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2
-ΔΔC
T method [122] as recommended by Life Technologies (Carlsbad, CA) since their 
TaqMan assay products meet the assumptions necessary for the appropriate application 
of the method [123]. Before the three replicates of each individual sample were 
combined to determine its average ΔCT, their concordance was examined to identify 
replicate failures, outliers, or excessive ranges. Individual samples with fewer than two 
of the three replicates succeeding were considered to have failed and were excluded 
from the analysis. Average ΔCT of each successful individual sample, having been 
normalized to ActB as the endogenous reference, was combined with the other 
individual samples in its category (uninfected susceptible, uninfected resistant, mock-
infected susceptible, mock-infected resistant, 8hr-infected susceptible, 8-hr infected 
resistant, 16hr-infected susceptible, or 16hr-infected resistant) to obtain a combined 
average ΔCT for each category. Before the three separate samples of individuals of one 
strain were combined for each category, a preliminary check was performed for 
concurrence of the data across individual samples to ensure no discrepancies or outliers 
existed and to establish awareness of any inappropriately wide ranges in average ΔCT 
values across individual samples. The ΔΔCT value was calculated using the susceptible 
WF/NHsd strain as the calibrator, and the resulting 2
-ΔΔC
T value was considered to 
represent fold change of the resistant strain gene expression as compared to the 
susceptible strain for each category. 
 In preparation for sequencing studies, quality of WF.LEW and WF/NHsd 
genomic DNA previously extracted from rat spleen tissue by phenol extraction with 
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ethanol precipitation [113] was assessed by a NanoDrop spectrophotometer (Thermo 
Fisher Scientific, Wilmington, DE) [124] and by gel electrophoresis on a 0.8% agarose 
gel to determine its suitability for high-throughput genomic sequencing. Qualifying 
samples were diluted to 50ng/ul using Buffer EB, and accurate concentration was 
verified using a Qubit® dsDNA BR Assay Kit and a Qubit 2.0 Fluorometer (Invitrogen). 
3ug each of WF.LEW and WF.NHsd genomic DNA was submitted to the DNA Core 
facility of the University of Missouri (Columbia, MO), where sequencing at a minimum 
depth of 8x coverage was performed on the HiSeq 2000 (Illumina, San Diego, CA). 
ELAND was used as the alignment algorithm to the rat v5.0 genome (with the Brown 
Norway (BN/SsNHsdMCW) rat strain as reference), and subsequent SNP, DIP, and 
CNV detection was performed utilizing CLC Genomics Workbench 5.1 (CLC Bio, 
Aarhus, Denmark), using stringent parameters to ensure accuracy of the resulting 
reports. 
 
Results and Discussion: qPCR 
The results obtained by qPCR analysis demonstrating determined fold 
differences in expression of the resistant WF.LEW strain compared to the susceptible 
WF/NHsd substrain can be seen in Table 3; a label of “Undetermined” indicates that too 
few replicates or samples succeeded in the qPCR reaction to perform the analysis. Those 
categories of various genes which showed a twofold or greater increase or decrease in 
expression in the resistant WF.LEW when compared to the susceptible WF/NHsd were 
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Table 3 Fold differences in expression of ROI genes in WF.LEW rats as compared to 
WF/NHsd rats under the conditions of four categories. Expression differences greater 
than twofold or less than half are highlighted in yellow.  
 
 
 
further examined and are summarized in Fig. 10. Interestingly, the only twofold-or-
greater differences in expression were increases in expression of WF.LEW genes over 
their WF/NHsd counterparts; no underexpression of WF.LEW genes as compared to 
WF/NHsd genes at this level of significance was observed. Several genes (Ythdf1, 
2.21209805 
2.007531094 
2.070657463 
2.180625465 
2.807166559 
2.019463401 2.982906314 
2.246969824 
2.314137269 2.042598522 2.345811175 
2.117146838 
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Kcnq2, Eef1a2, and Lime1) presented a fold difference of this magnitude only in 
uninfected animals; three other genes (Nkain4, Chrna4, and RGD1564340) showed it 
only in mock-infected specimens. Only two genes, Srms and Rtel1, exhibited a twofold 
or greater difference in expression in more than one category: Srms in two (both mock-
infected and 16-hour infected animals) and Rtel1 in three (mock-infected, 8-hour 
infected, and 16-hour infected animals.) It should be noted that Kcnq2, Eef1a2, Chrna4, 
RGD1564340, and Srms for the mock-infected condition were accepted for further 
consideration with one caveat: that as those particular results had CT values of around or 
slightly higher than 35, their reliability was somewhat questionable, as Life 
Technologies cautions for their TaqMan Gene Expression Assays that such high CT 
values approach the sensitivity limits of the qPCR system [123].  
 One would typically expect a higher basal level of gene expression (i.e., in the 
“Uninfected” category) to carry through the course of infection, particularly if the gene 
is connected with or responsible for resistance to the pathogen (provided that resistance 
is conferred based on expression level and not – or at least not solely – based on 
sequence, and therefore gene product, differences.) As such, those genes showing a 
greater-than-twofold difference in expression in the “Uninfected” category only were not 
considered prime candidates; furthermore, as only one sample of each strain was 
available for this state, the lack of robustness due to sample size was taken into 
consideration. Those genes presenting an appreciable difference in expression in the
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Fig. 10 Graphical representation of combined average ΔCT values for genes with greater than twofold 
expression differences of the resistant WF.LEW strain as compared to the susceptible WF/NHsd substrain. 
“Error bars” represent the range of average ΔCT values observed in that category for that strain; green 
boxes associate multiple categories under a single gene. 
 
 
 “Mock-Infected” category only were similarly dubious as one would also expect to 
observe differences in expression of the gene conferring resistance in the presence of the 
virus and throughout the course of infection. Furthermore, multiple replicate failures for 
RGD1564340 and Chrna4 lowered the robustness of those results for that category, and 
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a closer examination of the wide ranges of the average ΔCT across the three samples for 
this condition in Nkain4, Chrna4, and RGD1564340 revealed a notable lack of 
consistency in results (see Fig. 10.) Results from the “Uninfected” condition for gene 
Srms suffered the same deficiencies as previously mentioned for that category, but the 
gene’s nearly three-fold increase in WF.LEW expression compared to WF/NHsd 
expression in the “16-hour Infected” category merited further investigation. However, 
additional study revealed the seeming contradiction of a nearly twofold decrease in gene 
expression in mock-infected animals while each of the other conditions showed a rather 
marked increase, and furthermore, the extreme nature of the inconsistency among the 
three samples of the same category, particularly in the “16-hour Infected” category 
which showed the most dramatic fold difference in expression, became apparent. As can 
be observed in Fig. 10, while the combined average ΔCTs of the resistant and susceptible 
strains for this state may have differed by nearly 1.5 cycles, when it was noted that the 
range of the average ΔCTs among the three samples for the susceptible strain covered 
nearly 4 cycles and among the three samples for the resistant strain stretched over 5.5 
cycles, the excessive overlap of the resistant and susceptible ranges effectively nullified 
the impact of the purported three-fold difference for this condition. 
 Thus, the only gene left to consider was the promising Rtel1. With a greater-
than-twofold increase in expression in resistant animals in all infected categories and a 
nearly-twofold increase in resistant expression even in the uninfected category, 
consistency across all categories was present in the results for this gene. Additionally, 
the success of all replicates, and thus the presence of all samples in each category for 
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analysis, preserved the robustness of these results. All CT values measured were 
extremely uniform; the CT values of the three replicates for each sample varied by half a 
cycle at maximum, and most less than that, and variance in the resulting average ΔCT 
among the three samples of each strain for each condition (i.e., for all susceptible mock-
infected rats, all resistant mock-infected rats, all susceptible 8hr- or 16hr-infected rats, 
all resistant 8hr- or 16hr-infected rats, etc.) was minimal, again deviating by half a cycle 
at most, and with no overlap between the ranges of the resistant and of the susceptible 
strains. Furthermore, the combined average ΔCT values were approximately the same 
(less than half a cycle difference) across all susceptible rats in the mock-infected and 
infected categories and across all resistant rats in the mock-infected and infected 
categories. Of additional note was the fact that these highly shared combined average 
ΔCT values for the resistant or the susceptible animals, respectively, were approximately 
one full cycle less (implying a twofold increase in expression according to the 2
-ΔΔC
T 
method) from the uninfected animals of their strain, hinting that Rtel1 potentially may be 
induced by viral infection. Overall, the correlation of the differences between susceptible 
and resistant animals in combined average ΔCT values across all three significant 
categories was striking (see Fig. 10.) Thus, the weak or inconclusive results for the other 
19 genes in the ROI only served to emphasize the stark contrast of the clear, consistent, 
and robust results for gene Rtel1, marking it as a target for additional study. 
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Results and Discussion: Sequencing 
Sequencing results were addressed and analyzed next. In the process, one of the 
first things observed in the updated v5.0 rat assembly [121] was that three genes 
originally in the ROI (according to the v3.4 assembly) were missing: Birc7, Col20a1, 
and Helz2. According to the corresponding mouse and human RefSeq Genes, which 
were present in the new assembly, the overall gene order was still preserved; however, 
the homology proved too variable and inexact to predict the beginning and ending of 
these genes in the rat or the precise location of exons and introns. As such, SNP and DIP 
variations were mapped only to those 17 genes present in the ROI in the rat v5.0 
genome; thus, all SNPs and DIPs which formerly would have been identified as being 
within Birc7, Col20a1, or Helz2 were instead labeled as being intergenic between the 
remaining confirmed v5.0 rat genes. 
A summary and breakdown of the total variation discovered in the ROI between 
the resistant WF.LEW and susceptible WF/NHsd strains in the form of SNPs and DIPs 
can be seen in Fig. 11. Nearly 1000 differences were found in all, the vast majority of 
which were SNPs; slightly less than half of the variations were found within genes, and 
most of these were located in introns. As for the non-intronic variations, in total for the 
entire ~0.5Mb region, 13 5’UTR and 6 3’UTR variations were found along with 19 
SNPs in exons, 16 of which were synonymous SNPs (sSNPs) and 3 of which were non-
synonymous SNPs (nsSNPs) - two in exon 2 of gene Chrna4 and one in exon 1 of gene 
Kcnq2. As nsSNPs do not necessarily produce functional or structural consequences, a 
further examination of these three nsSNPs was conducted utilizing the online program  
 50 
 
 
 
 
Fig. 11 Breakdown of total variation between WF.LEW and WF/NHsd strains in the ROI discovered by 
sequencing analysis.  
 
 
 
SNAP (Screening for Non-Acceptable Polymorphisms) [125] to predict their effect on 
protein function. SNAP predicted the single nsSNP in Kcnq2 to be a neutral mutation 
with a fairly solid reliability index of 7, and while the program predicted the two nsSNPs 
found in Chrna4 to be non-neutral mutations, the low reliability index of 2 for each of 
these predictions lessened their impact and encouraged consideration of additional 
sequence analysis. 
 A different aspect of the sequencing analysis results is shown in Table 4, 
breaking down the differences by each gene and intergenic region and identifying the 
number of each type of variation (SNPs and DIPs) in each category. Additionally, 
graphical representations by gene of the location (exon, 5’UTR, 3’UTR, intron) and 
number and type (DIP, SNP, frameshift, non-frameshift, synonymous, non-synonymous) 
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Table 4 DIPs and SNPs by gene and intergenic region. Each (*) indicates a nsSNP. 
 
Gene Total Variations Type 
Ythdf1 19 
DIPs 
SNPs 
3 
16 
Intergenic 18 
DIPs 
SNPs 
2 
16 
Nkain4 43 
DIPs 
SNPs 
3 
40 
Intergenic 16 
DIPs 
SNPs 
1 
15 
Arfgap1 24 
DIPs 
SNPs 
3 
21 
Intergenic 99 
DIPs 
SNPs 
15 
84 
Chrna4 34 
DIPs 
SNPs 
4 
    30** 
Intergenic 112 
DIPs 
SNPs 
9 
103 
Kcnq2 122 
DIPs 
SNPs 
27 
  95* 
Intergenic 32 
DIPs 
SNPs 
3 
29 
Eef1a2 18 
DIPs 
SNPs 
2 
16 
Intergenic 72 
DIPs 
SNPs 
8 
64 
Ppdpf 5 
DIPs 
SNPs 
- 
5 
Intergenic 44 
DIPs 
SNPs 
7 
37 
Ptk6 30 
DIPs 
SNPs 
2 
28 
Intergenic 10 
DIPs 
SNPs 
- 
10 
Srms 10 
DIPs 
SNPs 
1 
9 
Intergenic 9 
DIPs 
SNPs 
- 
9 
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Table 4 Continued. 
 
Gene Total Variations Type 
RGD1564340 2 
DIPs 
SNPs 
- 
2 
Intergenic 26 
DIPs 
SNPs 
4 
22 
Gmeb2 15 
DIPs 
SNPs 
3 
12 
Intergenic 28 
DIPs 
SNPs 
5 
23 
Stmn3 26 
DIPs 
SNPs 
5 
21 
Intergenic 23 
DIPs 
SNPs 
4 
19 
Rtel1 40 
DIPs 
SNPs 
8 
32 
Intergenic 1 
DIPs 
SNPs 
- 
1 
Arfrp1 5 
DIPs 
SNPs 
1 
4 
Intergenic - 
DIPs 
SNPs 
- 
- 
Zgpat 21 
DIPs 
SNPs 
6 
15 
Intergenic 1 
DIPs 
SNPs 
- 
1 
Lime1 1 
DIPs 
SNPs 
- 
1 
Intergenic 6 
DIPs 
SNPs 
3 
3 
Zbtb46 22 
DIPs 
SNPs 
3 
19 
 
 
of each variation identified can be found in Appendix C, and Appendix D illustrates the 
position of each SNP and DIP in the rat v5.0 genome, broken down by gene. 
 Additional analysis performed on the sequencing data included an examination 
of differences in read coverage to look for indications of significant CNVs, of which no 
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prominent or conclusive evidence was found, and an exploration of structural variation 
between the two strains, which can be seen in Fig. 12. It was noted in this that both 
strains contained the same approximately 40Kb inversion within the region of 
179300000-179400000 on RNO3, slightly outside of the ROI (with the WF/NHsd 
substrain showing an additional ~36Kb complex variation in the same region) and that 
each also presented a notable structural variation on the other side of the ROI, within 
181000000-181500000 on RNO3 (an ~30Kb inversion in WF.LEW and an ~88Kb 
complex variation in WF/NHsd) as compared to the reference Brown Norway strain 
(BN/SsNHsdMCW) used to construct the v5.0 genome. The shared inversion and 
additional WF/NHsd complex variation above the ROI proved to both be in the 
intergenic region between genes Edn3 and Ntsr1; meanwhile, the WF.LEW inversion 
below the ROI contained gene Gata5, and the nearby WF/NHsd complex variation was 
located in the intergenic region between genes Polr3k and Mrgbp. Further investigation 
revealed a ~4.5Mb complex rearrangement involving this region at the distal end of 
RNO3 surrounding the ROI in the v5.0 genome as compared to the v3.4 genome. An 
illustration of the nature of this rearrangement can be seen in Fig. 13, but while worth 
noting, the ROI remained intact and did not appear to be clearly affected by this change. 
However, the structural variation analysis additionally indicated the presence of two 
noteworthy deletions within the ROI in the WF.LEW strain only: a 776bp intronic 
deletion within gene Kcnq2 (RNO3 180345935-180346710), and a 406bp intergenic 
deletion between genes Stmn3 and Rtel1 (RNO3 180529239-180529644). In 
conjunction with the previously obtained qPCR results, this considerable deletion in the 
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Fig. 12 Representation of relevant genes and structural variations in close proximity to the ROI on RNO3 
detected by sequencing analysis of WF/NHsd and WF.LEW. Relative sizes and distances are approximate. 
Genes are indicated in purple type, WF/NHsd variations in red type, and WF.LEW variations in green 
type. 
 
  
RNO3 
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Fig. 13 Chromosomal rearrangement observed in the rat v5.0 assembly as compared to the v3.4 assembly 
at the distal end of RNO3. The ROI is indicated in green. Figure is not to scale.  
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vicinity of Rtel1 was particularly intriguing and seemed to merit further investigation. 
 
Rtel1: Investigation and Promoter Search 
 Further investigation into the region that contained the 406bp deletion, ~2500bp 
upstream of the beginning of gene Rtel1, was performed in the form of a promoter 
search. The parameters of this search, which originally encompassed an area extending 
to approximately 4000bp upstream of the WF.LEW deletion, was eventually expanded 
to include the entirety of the preceding gene, Stmn3, thus covering an approximately 
14,000bp area from RNO3 180518000-180532000. Detection of CpG islands was 
achieved by use of the online program CpGProD [126], and the online program ProScan 
was utilized to search for promoters [127]; additionally, masking of repeat regions in the 
sequence prior to both analyses was performed using the RepeatMasker program [128], 
as defined in the instructions for the use of CpGProD. Results of this promoter search 
are summarized in Table 5 and illustrated in Fig. 14. As might be expected, one CpG 
island was detected by CpGProD and two promoters predicted by ProScan at the 
beginning of plus-strand gene Rtel1, with the CpG island and one of the two promoters 
predicted to be on the minus strand. Similarly, one CpG island and one promoter were 
reported, both on the minus strand, within the first ~1000bp of minus-strand gene Stmn3 
and around 10,000bp upstream of the 406bp intergenic deletion. A second minus-strand 
promoter was indicated in the middle of Stmn3, nearly 7000bp upstream of the deletion. 
Of further interest were an additional minus-strand CpG island and three additional 
putative promoters, two on the plus strand and one on the minus strand, reported near the 
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Table 5 Summary of CpG island and promoter predictions from CpGProD and ProScan, 
respectively. 
 
Prediction RNO3 Location Strand 
CpG Island 180518653-180519298 (-) 
Promoter 180518854-180519104 (-) 
Promoter 180522375-180522625 (-) 
Promoter 180525046-180525296 (-) 
Promoter 180525190-180525440 (+) 
CpG Island 180525519-180526445 (-) 
Promoter 180525957-180526207 (+) 
CpG Island 180531328-180532972 (-) 
Promoter 180531482-180531733 (-) 
Promoter 180531554-180531804 (+) 
 
 
end of Stmn3 and within ~4500bp of the intergenic deletion. 
 The prediction of promoter regions and a CpG island toward the middle and end 
of Stmn3 indicates the potential presence of distal regulatory elements, such as 
enhancers, silencers, insulators, or locus control regions, in this gene. The existence of a 
Stmn3 enhancer brought into closer proximity to the Rtel1 promoter by the 406bp 
intergenic deletion is one possible explanation of the increase in Rtel1 expression 
observed in resistant WF.LEW rats by the qPCR experiments. Enhancers have been 
proven to exert influence from a distance of several hundred kilobase pairs upstream or 
downstream of a core promoter and furthermore are orientation-independent elements, 
rendering the relative location of Rtel1 on the opposite strand from Stmn3 irrelevant to 
an enhancer’s capacity for action [129]. It is also possible that proximity is not the only 
factor but that the 406bp deletion could also potentially contain an undetected boundary 
or insulator element which, once eliminated, no longer successfully blocks Stmn3
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Fig. 14 Depiction of RNO3 chromosomal area involved in promoter search and of investigation results. The underlying chromosome is indicated in dark 
blue, green covers the area of each gene, the 406bp intergenic deletion is depicted in white, detected CpG islands are orange, and predicted promoters 
are light blue. Strand orientation of each element is indicated in black. 
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enhancer action upon the unrelated Rtel1 promoter [130]. Furthermore, by the process of 
transvection, an active enhancer on one chromosome has the ability, by chromosome 
pairing, to also affect transcription of the corresponding promoter on the homologous 
chromosome [131]. If the 406bp intergenic deletion is, in fact, responsible for allowing a 
Stmn3 enhancer to act upon the Rtel1 promoter and increase Rtel1 expression, then the 
phenomenon of transvection would further increase this effect. Thus, while it is possible 
that the observed resistance to RVF shows as a dominant trait because the increase in 
Rtel1 expression from only one allelic promoter is enough to confer resistance, the 
potential action of transvection should also be considered. A qPCR comparison of Rtel1 
expression in heterozygous F1 rats to homozygous P1 WF.LEW rats and homozygous 
P1 WF/NHsd rats could demonstrate whether an intermediate level of expression exists, 
suggesting that only one allelic promoter is being affected, or whether the heterozygous 
state mimics the homozygous resistant state, implicating the action of transvection. 
Clearly, additional studies are necessary to confirm these theories and further define the 
exact mechanism, but the evidence and potential explanations given here support a 
preliminary conclusion that Rtel1 is likely the gene responsible for conferring resistance 
to RVF in WF.LEW rats. Whether transvection is occurring or not, the theory of a 
potential Stmn3 enhancer brought into closer proximity to the Rtel1 promoter and 
perhaps no longer blocked by an insulator element is a tenable proposal with enough 
support to merit further investigation in the future. 
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CHAPTER VI 
CONCLUSIONS: CHARACTERIZATION OF FINAL PROPOSED GENE 
RTEL1 AND ITS POTENTIAL INTERACTIONS AND MECHANISMS 
 
Rtel1 
 Of the 20 genes in the narrowed ROI of RNO3, Rtel1 is the strongest candidate 
for providing RVF resistance in WF.LEW rats, based both on qPCR expression data and 
on sequencing results. The nearly-twofold increase in expression of Rtel1 at a basal level 
in uninfected WF.LEW rats compared to uninfected WF/NHsd rats, along with the 
exceptionally consistent greater-than-twofold increase in expression observed in all 
mock-infected and infected WF.LEW rats compared to mock-infected and infected 
WF/NHsd rats, is striking and furthermore unparalleled by the qPCR results from any of 
the other 19 genes. Moreover, the presence of 40 SNPs and DIPs within Rtel1 between 
the two strains, combined with a noteworthy 406bp deletion in the intergenic region 5’ to 
the gene’s starting point in WF.LEW, provides a correlation to and plausible basis for 
the observed difference in expression. The weight of evidence pointing to Rtel1 thus 
necessitates an examination of the nature and function of this gene to evaluate its 
tenability. 
The well-conserved Rtel1 gene encodes a helicase involved in regulating 
telomere elongation. Telomeres consist of DNA repeats at the end of linear 
chromosomes that function to stabilize and protect the ends of these chromosomes and to 
support overall genome stability [132]. Among vertebrates, this sequence of 
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(TTAGGG)n is highly conserved [133]. Interestingly, many DNA viruses also have 
terminal repeats, and viral-like elements have been suggested as the origins from which 
cellular telomeres and telomerase evolved [132,134]. This posited evolutionary 
relationship suggests the possibility of telomeres being potential targets for viruses, and 
indeed, evidence exists of both DNA and RNA viruses affecting host cell telomeres, 
including by interacting with host cell telomerase [134,135]. Telomerase itself has 
proven to be crucial for cell survival, not only by enzymatic activity on telomeric DNA 
synthesis but also via physical interactions to promote and maintain genome stability in 
dividing cells [136]. Rtel1 is likewise essential for maintaining telomere length but has 
similarly also proven itself vital for overall genome stability, with mice deficient in 
Rtel1 exhibiting not only global telomere loss but additionally chromosome fusions and 
breaks [137]. 
A study using mRtel1-deficient mouse ESCs revealed that mRtel1 is not only 
required for telomere replication of both the leading and lagging strands but is 
additionally a key protein for DNA replication, homologous recombination, and DNA 
repair [138]. Human RTEL1, with its non-coding readthrough transcript and also, 
through alternative splicing, multiple transcript variants encoding different isoforms, has 
likewise been shown to affect genome stability through its roles in regulating 
homologous recombination and in repairing DNA double-strand breaks (DSBs) by 
managing the disassembly of displacement loops (D-loops) [139]. These supplementary 
capacities of Rtel1 for genome stability and repair are not surprising, as the telomeres 
with which the helicase is involved as its primarily recognized function resemble fragile 
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sites, which challenge replication [140]. Telomeres form protective lariat-like structures 
called telomeric T-loops, which must be resolved before telomere replication can take 
place [141]. They are also guanine-rich regions, making them capable of forming stable 
secondary structures, such as G4-DNA [142], that may stall replication forks and 
possibly cause DNA breaks and loss of telomeric DNA [138]. Recent evidence points to 
human RTEL1’s role in dissociating these T-loops in a similar capacity to its mediatory 
action on D-loops elsewhere in the genome, and in resolving telomeric G4-DNA 
structures, reinforcing its importance both specifically at the telomeres and throughout 
the entire genome [137,143]. 
Rtel1 has proven not only to mirror telomerase in having function extending 
beyond merely telomere replication and maintenance but to be necessary itself for the 
competent action of telomerase on telomeres. In mouse ESCs, mRtel1 was found to 
localize transiently at the telomeres and furthermore to be required for telomere 
replication and extension, even when telomerase is present [138]; thus, it appears that 
telomerase is unable to carry out its main function without the presence of Rtel1 to help 
facilitate telomere elongation. It is therefore reasonable to theorize that the results of a 
lack or impairment of Rtel1 should mimic or encompass the detrimental effects of a lack 
of telomerase, such as those observed in a mouse study by Rudolph et al., 2000. It was 
found in these experiments that, when subjected to partial hepatectomy (PH) by surgical 
removal of 2/3 of the liver, mice null for the essential telomerase RNA (mTR) gene 
(mTR
-/-
), and thus telomerase-deficient, regenerated less liver mass than mTR
+/+
 mice 
with functional telomerase. Additionally, 3 out of 10 mTR
-/-
 mice died 48-72 hours after 
 63 
 
 
PH, and these exhibited shorter telomeres than the surviving mTR
-/-
 mice. Placed within 
the context of mitosis, these observations coincide with a regenerative wave of peak S-
phase activity at 24-48 hours and maximal mitosis by 72 hours post-PH. Thus, it was 
concluded that mTR
-/-
 mice are impaired in their cell progression through the mitotic 
cycle due to the genomic instability resulting from telomere loss, including observed 
chromosome fusions, the formation of anaphase bridges, and DNA double-strand breaks. 
This instability interferes with the regeneration process and delays the restoration of 
liver mass, and it furthermore potentially even triggers DNA damage responses to arrest 
growth and initiate increased apoptosis [144]. It is of note that the death time window of 
48-72 hours post-PH, presumably due to fatally reduced liver competency, observed in 
the compromised mTR
-/-
 mice in this study is seemingly quite similar in time and cause 
of death to the time of death at 48-72 hours from terminal liver disease seen in 
susceptible WF rats infected with RVFV [70, own data]; if Rtel1 is indeed responsible 
for this RVF resistance, then a lack of sufficient action due to lower gene expression 
very well might show similar results to those seen from an impairment or lack of 
telomerase, particularly in fellow rodents. Other studies have similarly linked short 
telomeres to liver disease and dysfunction, such as liver cirrhosis, even in the absence of 
any apparent mutation in telomerase [145]. Additionally, studies in humans with 
cirrhotic livers have found telomere shortening and senescence specifically in 
hepatocytes, with telomeres consistently short regardless of the age of the patient (age-
independent) or of the source of the cirrhosis (disease-independent), including when 
induced by viral hepatitis, and with hepatocellular senescence restricting the ability of 
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the injured organ to regenerate [146]. Clearly, even in the absence of a telomerase 
mutation, shortened telomeres and senescence in hepatocytes resulting from RVF-
induced hepatitis could conceivably be responsible for the liver failure and ensuing 
mortality observed in susceptible WF/NHsd rats, possibly because of a difference in the 
action of Rtel1 due to lower expression.  
In further support of a lack of Rtel1 causing mitotic impairment and potentially 
cell death, anaphase bridges, which are considered a hallmark of abnormal mitotic 
events, have similarly been recorded in RTEL1-deficient cells of humans suffering from 
Hoyeraal-Hreidarsson syndrome (HHS), along with other indicators of genomic 
instability such as spontaneous DNA damage and telomeric aberrations [147]. HHS, a 
clinically severe variant of the hereditary disorder dyskeratosis congenita (DC), is 
characterized by accelerated telomere shortening and dysfunction, which has been 
proven to occur even in the presence of active telomerase. HHS-causing mutations have 
been discovered in genes encoding various telomerase subunits and telomere proteins, 
and more recently, in RTEL1 [148]. Investigation of various RTEL1 mutations resulting 
in HHS symptoms has reinforced previous evidence of the roles of RTEL1 in enabling 
telomere elongation by telomerase and in properly resolving T-loops, and has further 
elucidated its functions in stabilizing telomeres, suppressing the DNA damage response, 
and repressing inappropriate recombination throughout the genome, emphasizing its 
action in both telomeric and non-telomeric aspects of cell function; furthermore, it has 
implicated the impairment or lack of RTEL1 as a cause of severe immunodeficiency (a 
prominent and serious symptom of HHS) [148,149]. The RTEL1 mutations investigated 
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in those experiments included compound heterozygous mutations as well as 
homozygous autosomal recessive mutations, and it must be addressed that while the 
concluding focus of the current study reported here proposes the work of an enhancer as 
the probable mechanism of increased Rtel1 expression conferring resistance to RVF by 
increasing or improving immune system response, it cannot be ruled out, without further 
study and evidence, that one or even several of the 40 SNPs and DIPs within Rtel1 found 
to differ between the resistant and susceptible strains could be responsible for or add to 
the effect, particularly in light of the fact that non-coding SNPs and sSNPs as well as 
nsSNPs in RTEL1 have a reported association with susceptibility to glioma [150]. 
Clearly this gene plays a significant role in immune system function, and even slight 
changes can have a noticeable physiological impact, potentially crippling immune 
response and increasing susceptibility to disease and dysfunction. 
 
TNFRSF6B 
Another potential theory to explain the rescuing action of Rtel1 involves the anti-
apoptotic TNFRSF6B decoy receptor gene of the tumor necrosis factor receptor 
superfamily. This theory connects the gene's genomic location immediately following 
RTEL1 on chromosome 20 in humans and on the opposite strand overlapping RTEL1 on 
chromosome 13 in cattle to the significance of tumor necrosis factor alpha (TNF-α) for 
hepatocytes in particular and for protection against viral hemorrhagic fever (VHF), 
particularly in the lack of a sufficient IFN response. 
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TNF-α is a cytokine mainly secreted by macrophages in response to an injury or 
pathogen; it has the capacity to induce apoptotic cell death and to inhibit viral replication 
[151]. Macrophages are the primary component of the reticuloendothelial system, and 
these largely mediate the innate resistance or susceptibility of animals to viral infections 
due to their functions of monitoring the body, of clearing the bloodstream of viral 
particles, and of controlling the entry of viruses into target organs, including the liver. 
Macrophages play an important role in the infection and growth of viruses in the liver, as 
the virus must pass through a macrophage “barrier” in order to reach hepatic cells [152]. 
Disease resistance may originate from the relative susceptibility of the macrophages 
themselves to viral hepatitis, as seen in a study by Bang and Warwick, 1960, in which a 
genetic difference in susceptibility of two mouse strains to mouse hepatitis was 
determined to be linked to the survival or destruction of mouse liver macrophages [153]; 
however, RVFV appears not to directly infect liver macrophages but instead to be taken 
up by them and then passed on to hepatic cells [152]. It has been acknowledged that 
macrophages play a significant role in the pathogenesis of RVF viral infection, as 
enhancing macrophage function by stimulation with glucan prior to infection reduces the 
pathogenicity of RVFV in mice, increasing their survival rate from 50% to 84% [154]; 
thus, a different immune function of macrophages, such as their secretion of TNF-α, may 
be the factor that plays an important part in RVF resistance. Interestingly, in a similar 
later experiment, pre-glucan-treatment of mice which were subsequently infected with 
RVFV only delayed death; however, the cause of these deaths was encephalitis rather 
than hepatitis [72]. As such, it appears that in this case macrophage stimulation 
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preserved and protected the liver of these rodents but failed to effect clearance of the 
virus from the bloodstream and thus allowed infection of the brain, mimicking the 
results observed in the RVFV infection of resistant LEW rats which are protected from 
hepatic disease but may occasionally succumb to encephalitis [70].  
As referenced earlier, a delayed IFN response to RVFV is correlated with 
mortality in rhesus monkeys [68], suggesting that a prompt immune response is critical 
in limiting the severity of RVF disease. It is speculated that the RVFV NSs protein must 
be a potent repressor of IFN type I production early on, perhaps using its inhibition of 
TFIIH to limit IFN transcription. While this inhibition of general transcription means 
that viral transcription by the captive host cell is restricted and slowed as well, it appears 
that this disadvantage in viral growth is worth the benefit of preventing an IFN response 
[44]. The Ebola virus, another cause of VHF, similarly produces a protein with 
antagonistic function toward IFN type I (VP35), and for it as well, early immune 
response has been implicated as the determining factor in the restriction of viral 
replication and in successful recovery from the disease; however, from observation of 
asymptomatic Ebola virus infection in human patients, an early and strong cytokine 
response that included TNF-α effectively controlled viral dissemination and protected 
against fatality in the absence of a sufficient IFN response [155,156]. Thus, it appears 
possible for macrophage-produced TNF-α to help provide a successful immune response 
against VHFs when IFN action is inadequate. This throws into an interesting light 
previous evidence that female Lewis rats (LEW/N) demonstrate a defect in the 
production of glucocorticoids, hormones responsible for the immunosuppression of NF-
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κB, a transcription factor induced by TNF-α. This lowered glucocorticoid production 
level would inhibit immunosuppression, resulting in the increase in autoimmune 
inflammatory diseases such as arthritis observed in the study but also presumably 
resulting in an increase in antiviral function via this TNF-α-induced pathway in Lewis 
rats [157]. 
TNF-α is not only related to VHF survival but to liver function as well. In 
striking similarity to the critical nature of telomerase for liver regeneration mentioned 
previously, rats lacking TNF-α action and mice lacking the TNF-R1 receptor likewise 
demonstrated an inability to recover from partial hepatectomy, showing decreased DNA 
synthesis, delayed liver restoration, and higher fatality than the respective wild-type 
[158,159]. Curiously, both the hepatitis B and C viruses induce TNF-α expression in the 
human liver, and elevated serum levels of TNF-α have been observed in patients 
exhibiting fulminant hepatitis, with those levels significantly higher in fatal cases than in 
survivors [160,161]. This possibly implicates TNF-α in initiating or perpetuating liver 
damage in hepatitis, perhaps related to the cytokine’s function of inducing apoptosis, as 
through this mechanism, TNF-α has proven to be capable of aggravating liver injury. 
Co-administration of TNF-α with D-galactosamine (GaIN) to inhibit the transcription of 
hepatocytes and therefore induce liver injury activates apoptosis of mouse hepatocytes, 
both in vivo and in vitro [162]. Evidence indicates that the TNF-R1 receptor is involved 
in this pathway, as TNF-R1 knockout mice are resistant to this treatment; interestingly, 
TNF-R2 receptor knockout mice are more susceptible than wild-type mice, which can 
perhaps be explained by the fact that without TNF-R2, more TNF-α is available to bind 
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to TNF-R1 and induce apoptosis, thus increasing the cytotoxic effect [163,164]. 
Considering the effects of competitive binding, a decoy receptor that inhibits apoptosis, 
such as TNFRSF6B, could function in a similar capacity and produce a comparable 
effect to the presence of competing receptor TNF-R2 in mitigating apoptosis and 
preventing further liver injury. 
Part of the TNF receptor superfamily, the product of gene TNFRSF6B acts as a 
decoy receptor that competes with death receptors for binding of apoptosis-mediating 
ligands FasL, LIGHT, and TL1A. This gene thereby plays a role in regulating apoptosis 
by providing protection against it, which explains why overexpression of this gene has 
been observed in tumors of various tissues [165]. A readthrough transcript from RTEL1 
into TNFRSF6B exists in humans, although this RTEL1-TNFRSF6B transcript 
generated is non-coding. Currently, no RTEL1-TNFRSF6B readthrough transcript is 
annotated in the rat v5.0 genome, nor has a mouse or rat gene homologue to TNFRSF6B 
been identified anywhere in their respective genomes; however, a study of basal 
macrophages from Wistar-Kyoto rats (WKY/NCrl) and Lewis rats (LEW/Crl), which are 
susceptible and resistant, respectively, to crescentic glomerulonephritis (CRGN), 
discovered four differentially expressed, alternatively spliced isoforms of Rtel1 between 
the two strains [166]. It therefore does not seem unreasonable to assume that currently 
unannotated transcripts may exist which have yet be identified. (It is additionally 
interesting to note that, for all four isoforms, Rtel1 expression in the resistant LEW rats 
was higher than in the susceptible WKY rats.) Fascinatingly, TNFRSF6B gene therapy 
was demonstrated in mice to be effective in preventing the development of autoimmune 
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crescentic glomerulonephritis (ACGN), a variant of CRGN, at least partially due to 
inhibiting apoptosis [167]; thus, there is evidence of the amplified presence of both Rtel1 
and TNFRSF6B providing protection from or resistance to disease. Moreover, in vivo 
treatment of a murine model with a TNFRSF6B analogue was discovered to alleviate 
lung inflammation caused by FasL, further illustrating its potential therapeutic utility; 
also, TNFRSF6B inhibits FasL-mediated cell death in human hepatocytes in vitro, and 
pre-treatment with TNFRSF6B prevents FasL-produced fatality in mice, ostensibly by 
attenuating FasL-induced hepatocyte apoptosis [168,169]. Naturally increased 
TNFRSF6B expression has been observed in human chronic liver disease, which may 
facilitate liver cell survival through its anti-apoptotic activity [170]. Thus, TNFRSF6B 
can be beneficial under disease conditions, including particularly to the liver. 
While apoptosis of virus-infected hepatocytes can contribute to viral clearance, it 
can also result in excessive or unnecessary destruction of liver cells once the apoptotic 
pathway has been activated, leading to liver dysfunction and possible necrosis. For 
example, during the acute phase of hepatitis B virus (HBV) infection, a significant 
proportion of hepatocytes are infected and likely replicating the virus; however, 
widespread apoptosis of these liver cells in an attempt to control viral spread would 
greatly damage this vital organ of the host. Thus, apoptosis is not universally 
advantageous for the infected host, making an anti-apoptotic factor such as TNFRSF6B 
valuable for host survival [151,171]. Both TNF and FasL are implicated in the injury of 
liver cells, with TNF additionally suspected of potentially directly causing organ failure 
via a “suicide program” under disease conditions [163,170]. Furthermore, TNF-α can 
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affect FasL apoptotic activity, as its regulation of FasL-mediated apoptosis has been 
observed both in vivo & in vitro in mice, and an in vitro study of human eosinophils 
discovered that TNF-α together with IFN-γ increases expression of the Fas cell surface 
death receptor (CD95) and thereby increases FasL-induced apoptosis [172,173]. Thus, 
while macrophage production of TNF-α appears to be capable of helping to compensate 
for the lack of IFN type I response by itself participating in inducing a sufficient immune 
response to provide resistance to VHFs similar to RVF, it is possible that an unintended 
additional effect of this TNF-α production could be increased inducement of apoptosis, 
particularly in infected hepatocytes, via its influence on FasL, leading to fatal liver 
necrosis. It is therefore plausible that decoy receptor TNFRSF6B, by competing with 
death receptors, prevents ensuing liver necrosis due to unrestrained host-immune-
system-mediated apoptosis related to TNF, allowing the host to survive hepatic disease 
while TNF-α induces its cascade, assisting in initiating a successful immune response 
against RVFV in lieu of proper IFN action. Additional subsequent factors of resistance 
may include the limitations of transcription via TFIIH due to the inhibitory action of 
RVFV NSs becoming disadvantageous to the virus by slowing its replication enough for 
it to be overwhelmed by the TNF-α-induced immune response, and possibly the 
assistance of the elevated levels of TNF-α in eventual liver regeneration. While the 
involvement of TNFRSF6B in this pathway would require confirmation, the potential 
implications of its established location relative to RTEL1 in the human and cattle 
genomes should not be ignored. The protection that an anti-apoptotic decoy receptor 
such as TNFRSF6B could conceivably provide to target organs of RVFV, such as the 
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liver, while macrophage-secreted TNF-α participates in inducing a sufficient early 
immune response in compensation for deficient IFN action, is an interesting theory of 
action that demands further attention. 
 
Summary and Conclusions 
In light of this current study that identifies Rtel1 as the most likely candidate 
gene for providing resistance to RVFV, its established role as a regulator of telomere 
elongation correlates to the postulated evolutionary and proven interactive relationships 
between viruses and telomeres; moreover, recent evidence clearly shows that it affects 
several additional processes and is involved in various other pathways. Previous 
evidence indicating the critical nature of Rtel1 for genome stability, its necessity for the 
proper functionality of telomerase, its implied effect on principal mitotic events, and its 
considerable influence on the immune system, all corroborates the acquired data of this 
study indicating Rtel1 to be the gene of significance conferring resistance to RVFV in 
WF.LEW rats. Additionally, its potential association with TNFRSF6B, especially in 
light of the proven effects of TNF-α in connection with the liver and with VHFs and 
considering the protective aspects of the anti-apoptotic decoy receptor itself, further 
endorses the candidate gene status of Rtel1. Further exploration and confirmation, 
through studies such as Rtel1 gene knockdown in resistant WF.LEW rats and the use of 
targeted excision, via methods such as Cre-Lox recombination, of the purportedly 
responsible 406bp intergenic deletion in susceptible WF/NHsd rats to mimic the 
structure of the WF.LEW genomic region, will be necessary to verify these conclusions 
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and to determine the exact pathway and mechanism by which this resistance is attained, 
but based on the evidence gathered by this current study, further supported by its known 
functions and established consequential nature, Rtel1 remains a promising final 
candidate gene for additional investigation in order to eventually provide a basis for the 
development of new protective and preventive measures against RVFV in threatened 
target species. 
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APPENDIX A 
SSLP MARKERS AND SIZES* 
 
Marker LEW/SsNHsd LEW/Crl WF.LEW LEW/MolTac WF/NHsd WF/Crl 
RH140313 211 211 211 211 211 211 
BI301396 231 231 231 231 231 231 
D3Wox1 216 216 218 224 218 220 
BF412371 148 148 148 148 148 148 
BF401071 220 220 220 220 220 220 
*Allele sizes include the additional 19 base pairs of the M13 primer. 
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APPENDIX B 
SNP MARKERS AND ALLELES 
 
Marker LEW/SsNHsd LEW/Crl WF.LEW LEW/MolTac WF/NHsd WF/Crl 
rs8149191 T T T T T T 
rs8164532 A A A G G G 
rs8154944 A A A G G G 
rs8163789 A A A G G G 
rs8168846 G G G G G G 
rs8152155 G G G G G G 
rs8156398 C C C T T T 
rs8164870 T T T T T T 
rs8166193 G G G G G G 
rs8146600 T T T T T T 
rs8145897 C C C C C C 
rs8167610 G G G A A A 
rs13457129 C C C G G G 
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APPENDIX C 
ROI SNP AND DIP BREAKDOWN BY GENE 
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APPENDIX D 
ROI SNP AND DIP POSITIONS BY GENE 
 
  
 119 
 
 
 
  
 120 
 
 
 
  
 121 
 
 
 
  
 122 
 
 
 
  
 123 
 
 
 
  
 124 
 
 
 
  
 125 
 
 
 
  
 126 
 
 
 
  
 127 
 
 
 
  
 128 
 
 
 
  
 129 
 
 
 
  
 130 
 
 
 
  
 131 
 
 
 
  
 132 
 
 
 
  
 133 
 
 
 
  
 134 
 
 
 
 
